Essent Biologics, a nonprofit biotechnology company, announced its launch to provide human-derived biomaterials and 3D biology data to the regenerative medicine research community, as well as producing key inputs for further manufacturing by clinical partners.
As a new venture from AlloSource, a manufacturer of fresh cartilage tissue for joint repair and skin allografts to heal severe burns, Essent Biologics plans to leverage its connection to human tissue donation by providing low passaged primary cell lines, origin tissue, and donor data to help advance translational research from benchtop to bedside. The company also has the capability to serve as a biomanufacturing partner, creating a large inventory of custom products, according to Corey Stone, executive director, Essent Biologics.
“Essent will motivate and empower the work researchers are doing by supporting the development of innovative therapies through quality biomaterials and powerful data,” he said, adding that Essent will supply highly characterized human mesenchymal stem cells (MSCs) produced under current cGMP. The company has already partnered with academic research groups and biopharmaceutical companies (e.g., Validus Cellular Therapeutics). Essent Biologics’ official product launch is anticipated in April.
According to Allied Market Research, the cellular therapy and tissue engineering industries are some of the fastest growing in the regenerative medicine sector. The cellular therapy market value was $7.25 billion in 2019 and is expected to reach $48.11 billion by 2027.
The tissue engineering market is expected grow from $2.3 billion in 2019 to $6.8 billion by 2027.
